Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;79(10):2662-2667.
doi: 10.1093/jac/dkae273.

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view

A Cingolani  1   2 , A Tavelli  3 , S De Benedittis  3 , I Mastrorosa  4 , C Muccini  5 , T Bini  6 , A Carraro  6 , M Compagno  7 , M Mazzitelli  8 , M Guastavigna  9 , M Cernuschi  5   10 , C Torti  1   2 , A Antinori  4 , A d'Arminio Monforte  3 ; ICONA Foundation Study group
Collaborators, Affiliations

Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view

A Cingolani et al. J Antimicrob Chemother. .

Abstract

Background: Implementation level of long-acting injectable agents cabotegravir/rilpivirine (LAI CAB/RPV) for human immunodeficiency virus (HIV) treatment in Italy is still not known. The aim of this study is to identify the status of implementation of LAI CAB-RPV and its barriers.

Materials and methods: A cross-sectional online survey was conducted among infectious diseases (ID) physicians and nurses belonging to the ICONA network in Italy. Three validate 4-items measures were used: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM).

Results: Out of 61 ICONA centres, 38 (62%) completed the survey: 57.9% were academic centres, 42.1% were hospital-based. In total, 104 respondents were ID physicians (57.4%), 77 were nurses (42.5%); 4.5% of all PWH followed at the 38 centres started LAI CAB/RPV at time of study. Centres taking care of >1000 PWH reported 95% application of procedures for LA implementation, higher than other centres (P = 0.009). Mean score of AIM was (16.0, standard deviation, SD, 3.3), of IAM (16.0, SD 3.0) and FIM (16.0, SD 2.9). A linear correlation was found between AIM and the number of people with HIV who started LAI CAB/RPV (25-50 versus <25, coefficient of correlation [b] 2.57, 95%CI 0.91-4.60, P = 0.004), academic versus hospital-based centres (b -1.59, 95%CI -2.76-0.110044, P = 0.007) and the absence of preliminary systematic assessment of staff (b -1.98, 95%CI -3.31-0.65, P = 0.004). Implementation barriers were not significantly different according to the number of PWH/centre.

Conclusions: LAI CAB/RPV implementation was low, with a great variability according to centre size. Tailored and centre-specific interventions to address barriers and to optimize the LA treatment implementation should be designed.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Percentage of participants who responded ‘agree’/‘completely agree’ on the 1–5 Likert scale for each item of the FIM, IAM and AIM. The two answers are summed together to express the proportion of participants with a positive response to each question. Mean scores with ±SD are also reported for the three implementation measures (scale 4–20).
See this image and copyright information in PMC

References

    1. Swindells S, Andrade-Villanueva J-F, Richmond GJ et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med 2020; 382: 1112–23. 10.1056/NEJMoa1904398 - DOI - PubMed
    1. Orkin C, Arasteh K, Górgolas Hernández-Mora M et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med 2020; 382: 1124–3. 10.1056/NEJMoa1909512 - DOI - PubMed
    1. Jaeger H, Overton ET, Richmond G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV 2021; 8: e679–89. 10.1016/S2352-3018(21)00185-5 - DOI - PubMed
    1. Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023; 76: 1646–54. 10.1093/cid/ciad020 - DOI - PMC - PubMed
    1. DHHS . Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2024. https://clinicalinfo.hiv.gov/en/about-clinicalinfo